

STING

The next candidate for cancer immunotherapy.



Why target STING?



STING

Tumor cells have mechanisms to hide from patient's immune responses. STING pathway remains dormant.

Synthetic agonist

To activate the STING pathway, an agonist which mimics STING's natural ligand is synthetized.

Activated STING

The agonist can be administrated directly into the tumor area. It will activate STING. Patient's immunity is stimulated.

References

1. Science 2013, DOI: 10.1126/science.1232458)
2. Madei T, Lanczycki CJ, Zhang D, Thiessen PA, G

2. Madej T, Lanczycki CJ, Zhang D, Thiessen PA, Geer RC, Marchler-Bauer A, Bryant SH. " MMDB and VAST+: tracking structural similarities between macromolecular complexes. Nucleic Acids Res. 2014 Jan; 42(Database issue):D297-303

Check the Revvity website and follow us! www.revvity.com



940 Winter StreetWaltham, MA 02451 USA

www.revvity.com